Loading organizations...
§ Private Profile · Lille, Nord-Pas-de-Calais, France
Clinical-stage biopharmaceutical company developing DMOADs, with candidate 4P004 for knee osteoarthritis.
4Moving Biotech is a clinical-stage biopharmaceutical company developing disease-modifying osteoarthritis drugs, based in Lille, France. The organization focuses on creating intra-articular GLP-1 analog candidates, such as its lead asset 4P004, designed to halt cartilage degradation and reduce joint inflammation for patients with knee osteoarthritis. The enterprise has raised approximately €30 million in total funding to date, which includes a recent €12 million financing round and a €7.6 million grant from the France 2030 initiative. Operating as a majority-owned subsidiary of 4P-Pharma, the company also maintains academic and financial ties with entities such as Sorbonne University and Seventure Partners. Following the completion of Phase 1 clinical trials, the firm is currently advancing its Phase 2a INFLAM-MOTION study and expanding its clinical operations into the United States. 4Moving Biotech was founded in 2020 by Revital Rattenbach and Francis Berenbaum.
4Moving Biotech has raised $14.3M across 1 funding round.
4Moving Biotech focuses on developing disease-modifying osteoarthritis drugs (DMOADs), including 4P004, a potential first-in-class GLP-1 therapy for knee osteoarthritis. This approach aims to target the underlying disease rather than just symptoms.
4Moving Biotech focuses on developing disease-modifying osteoarthritis drugs (DMOADs), including 4P004, a potential first-in-class GLP-1 therapy for knee osteoarthritis. This approach aims to target the underlying disease rather than just symptoms.
4Moving Biotech has raised $14.3M across 1 funding round. Most recently, it raised $14.3M Undisclosed in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 10, 2026 | $14.3M Undisclosed | — | — | Announced |
4Moving Biotech is a clinical-stage biopharmaceutical company dedicated to pioneering research and development in the field of osteoarthritis (OA). Founded in 2020, the company focuses on creating first-in-class breakthrough therapies to address the unmet medical needs of OA patients. Its mission centers on restoring mobility to improve the quality of life for individuals affected by this condition.
The company's therapeutic strategy involves developing disease-modifying osteoarthritis drugs (DMOADs). A key candidate in its pipeline is 4P004, which is being investigated as a potential first-in-class GLP-1 therapy specifically targeting knee osteoarthritis. This approach aims to provide novel treatment options beyond symptomatic relief by targeting the underlying disease mechanisms.
4Moving Biotech has advanced its lead candidate, 4P004, into clinical development. The company recently announced the enrollment of the first patient in a Phase 2a trial for this therapy, marking a significant step in its development. This progression follows the receipt of an FDA Investigational New Drug (IND) clearance, which permits the initiation of clinical studies in the United States.
To support its ongoing research and development efforts, 4Moving Biotech successfully closed a €12 million financing round. This funding is intended to further advance its DMOAD pipeline, particularly its first-in-class candidate for knee osteoarthritis. The company operates from its headquarters located in Lille, Nord-Pas-de-Calais, France, contributing to the European biotech ecosystem.